Researchers presented new evidence for using circulating tumor DNA to tailor treatment in oligometastatic cancers at ESTRO 2026, highlighting a blood-based approach aimed at improving how therapy is selected and sequenced. The study introduced a new ctDNA biomarker strategy using plasma measurements to inform treatment decisions, positioning ctDNA as a practical tool for refining outcomes in patients with limited metastatic spread.